Alleged Off-label Promotion of Epilepsy Medication Results in $214.5 Million Resolution

Irish pharmaceutical manufacturer Elan Corporation, PLC, its U.S. subsidiary, Elan Pharmaceuticals, Inc., and Japanese drug manufacturer Eisai, Inc., have all agreed to pay a total for $214.5 million to resolve allegations of off-label promotion of Zonegran, an epilepsy drug. Elan Pharmaceuticals agreed to plead guilty to misbranding Zonegran, which was approved by the FDA in…

Read More

Kos Pharmaceuticals Settle Kickback and Off-Label Promotion Charges

Delaware-based Kos Pharmaceuticals ageed to pay more than $41 million to resolve alleged misconduct relating to its drugs Advicor and Niaspan.  Kos, a subsidiary of Abbott Laboratories, will pay $38 million to settle charges that it offered doctors and other medical professionals and organizations money, free travel, grants, honoria and other goods and services to…

Read More

Student Aid Lenders Settle Whistleblower Suit for $57.75 Million

Nelnet Inc. and Nelnet Educational Load Funding Inc., Brazos Higher Education Authority and Brazos Higher Education Service Corp, Panhandle Plains Higher Education Authority and Panhandle Plains Management and Servicing Corp have settled a False Claims suit for a total of $57.75 million. The suit was brought by Dr. Jonathan Oberg, a former Department of Education…

Read More

Ameritox to Pay $16.3 Million to Settle False Claims Lawsuit

Midland, TX-based Ameritox, a drug-testing company that serves 10,000 doctors and two million patients in 28 states, has settled claims that they paid kickbacks to doctors for $16.3 million. Ameritox faced allegations that it paid doctors to win their Medicare business. The original whistle-blower in the case, Debra Maul, will receive $3.4 million of that…

Read More

New York Times Reports on GlaxoKlineSmith Product Contamination Settlement

An article in The New York Times reported on the Getnick & Getnick groundbreaking whistleblower case that resulted in GlaxoKlineSmith’s $750 million settlement for knowingly selling contaminated baby ointment and ineffective antidepressants. The New York Times stated that GlaxoSmithKline “sold 20 drugs with questionable safety that were made at a huge plant in Puerto Rico…

Read More

Getnick & Getnick Wins $750 Million Settlement for GlaxoSmithKline Medicaid Fraud

In a groundbreaking case, the first time the whistleblower law was used to hold drug makers accountable for violations of government manufacturing standards, GlaxoSmithKline (GSK) will pay $750 million to settle civil and criminal charges that it manufactured and sold adulterated drugs to Medicaid and other government health plans. This settlement is a result of…

Read More